What is the main business of Optiferric?

The main business activity of Optiferric focuses on manufacture of pharmaceutical preparations.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on May 19, 2015.

Where is the headquarters located?

The headquarters is located at: ul. Geodetów 23C, 05-509 Józefosław.

Who is on the management board?

The management board includes Mariusz Radosław Cięciara (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 105,000 (approx. $28,363).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What was the revenue?

The company reported a revenue of $816,162 in 2025, which is an increase of 26.9% compared to 2024.

Is the company profitable?

Yes, the company recorded a net profit of $78,711 in 2025.

What is the main operating cost?

The largest operating cost category falls under other operating costs. This category amounted to $583,249 in 2025, representing 81% of all operating expenses.

Optiferricsp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2015-05-19

Share capital

105 000,00 PLN

Activity description

Optiferric has worked with small and medium-sized companies and multinational corporations since 2015, supplying products for iron supplementation. Its team has experience in product and business development, marketing, and pharmaceutical production.

Registered address

ul. Geodetów 23C/2, 05-509 Józefosław, Poland

Website

optiferric.com

Electronic delivery address

AE:PL-61541-58466-UDJGA-25

Financials

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 816.16kMedianUSD 782.27kAverageUSD 24.03m

Net profit

This companyUSD 78.71kMedianUSD 7.91kAverageUSD 2.59m

Operating costs

This companyUSD 723.93kMedianUSD 723.93kAverageUSD 19.92m

Assets

This companyUSD 785.17kMedianUSD 800.34kAverageUSD 29.11m

Industry

Bank accounts

Registered as a VAT taxpayer on 2015-06-11. Active

mBank
71 1140 2004 0000 3612 0424 2830
mBank
15 1140 2004 0000 3002 7570 9110

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Public aid

No public aid cases recorded in the last 10 years.

Tenders

No recorded participation in tenders.

Regulatory authorisations

Authority	Type	Status
BDO	BDO register entry	Active

Authorized Representatives

Piotr Adam Kłys – Management Board Member

Artur Piotr Wrzosek – Management Board Member

Mariusz Radosław Cięciara – President of the Management Board

Manner of representation

The company may be represented by the President of the Management Board jointly with another member of the management board.

Ownership

Owner	Shares	Share value	Stake
Felix Familia Fundacja Rodzinna	35	$9,454.35	33.3333%
Piotr Adam Kłys (48)	35	$9,454.35	33.3333%
Artur Piotr Wrzosek (49)	35	$9,454.35	33.3333%

Beneficial owners

Person	Rights

Competitors

Name	Revenue	Website
Labofarmsp. z o.o.	$6,814,569.78	labofarm.pl
Actifarmsp. z o.o.	$2,151,476.85	actifarm.pl
F1 PharmaS.A.	$272,113.66	f1pharma.pl

FAQ

Last updated: 2026-05-21